Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $17.00 Average Target Price from Brokerages

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has earned a consensus recommendation of “Moderate Buy” from the five analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $17.00.

A number of analysts recently commented on the company. HC Wainwright raised Artiva Biotherapeutics to a “buy” rating and set a $12.00 target price for the company in a research report on Wednesday, June 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Artiva Biotherapeutics in a report on Saturday, September 27th.

Insider Buying and Selling

In other Artiva Biotherapeutics news, CEO Fred Aslan sold 25,500 shares of the company’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $2.73, for a total transaction of $69,615.00. Following the transaction, the chief executive officer owned 386,693 shares in the company, valued at approximately $1,055,671.89. This represents a 6.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 21.40% of the company’s stock.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Marshall Wace LLP acquired a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth about $79,000. Nuveen LLC bought a new stake in Artiva Biotherapeutics during the 1st quarter worth approximately $144,000. Jane Street Group LLC purchased a new stake in shares of Artiva Biotherapeutics in the second quarter worth approximately $67,000. Qube Research & Technologies Ltd bought a new position in shares of Artiva Biotherapeutics in the second quarter valued at approximately $58,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Artiva Biotherapeutics during the second quarter valued at approximately $53,000.

Artiva Biotherapeutics Stock Performance

Artiva Biotherapeutics stock opened at $2.95 on Friday. Artiva Biotherapeutics has a 12-month low of $1.47 and a 12-month high of $16.87. The firm’s fifty day moving average is $2.85 and its 200 day moving average is $2.45.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.03). As a group, equities research analysts predict that Artiva Biotherapeutics will post -4.95 EPS for the current fiscal year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.